Note L - Concentration	12 Months Ended
Dec. 31, 2024
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE L— CONCENTRATION Milestone Scientific has informal arrangements with third-party U.S. manufacturers of the STA devices, and epidural instruments pursuant to which they manufacture these products under specific purchase orders which contains advance payments for long lead items for production. Advances on contracts have been classified as current at December 31, 2024 and 2023. The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientific’s ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of termination of such a relationship, would have a material adverse effect on Milestone Scientific’s financial condition, business, and results of operations. On January 3, 2023, the Company launched an E-Commerce platform selling and shipping STA Single Tooth Anesthesia System® (STA) and handpieces directly to dental offices and dental groups within the U.S. For the year ended December 31, 2024, E-Commerce accounted for 60% of net product sales. For the year ended December 31, 2023, E-Commerce accounted for 48% of net product sales. The Company had three distributors that accounted for 22%, 13% and 11% of accounts receivable, respectively, as of December 31, 2024. The Company had three distributors that accounted for 39%, 38%, and 15% of accounts receivable, respectively as of December 31, 2023. As of December 31, 2024, the Company had two suppliers that accounted for 31% and 30%, respectively, of accounts payable and accounts payable, related party. The Company had three vendors that accounted for 37%, 17% and 12%, respectively of accounts payable and accounts payable, related party as of December 31, 2023.

Note L - Concentration

12 Months Ended

Dec. 31, 2024

Concentration Risk Disclosure [Text Block]

NOTE L— CONCENTRATION

Milestone Scientific has informal arrangements with third-party U.S. manufacturers of the STA devices, and epidural instruments pursuant to which they manufacture these products under specific purchase orders which contains advance payments for long lead items for production. Advances on contracts have been classified as current at December 31, 2024 and 2023. The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientific’s ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of termination of such a relationship, would have a material adverse effect on Milestone Scientific’s financial condition, business, and results of operations.

On January 3, 2023, the Company launched an E-Commerce platform selling and shipping STA Single Tooth Anesthesia System® (STA) and handpieces directly to dental offices and dental groups within the U.S. For the year ended December 31, 2024, E-Commerce accounted for 60% of net product sales. For the year ended December 31, 2023, E-Commerce accounted for 48% of net product sales.

The Company had three distributors that accounted for 22%, 13% and 11% of accounts receivable, respectively, as of December 31, 2024. The Company had three distributors that accounted for 39%, 38%, and 15% of accounts receivable, respectively as of December 31, 2023.

As of December 31, 2024, the Company had two suppliers that accounted for 31% and 30%, respectively, of accounts payable and accounts payable, related party. The Company had three vendors that accounted for 37%, 17% and 12%, respectively of accounts payable and accounts payable, related party as of December 31, 2023.